Compare RYAM & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYAM | CLLS |
|---|---|---|
| Founded | 1926 | 1999 |
| Country | United States | France |
| Employees | N/A | 222 |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 422.1M | 485.6M |
| IPO Year | N/A | 2007 |
| Metric | RYAM | CLLS |
|---|---|---|
| Price | $5.84 | $4.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 544.0K | 116.7K |
| Earning Date | 11-04-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,471,356,000.00 | $82,551,000.00 |
| Revenue This Year | N/A | $32.58 |
| Revenue Next Year | $6.99 | $20.68 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 129.04 |
| 52 Week Low | $3.35 | $1.10 |
| 52 Week High | $8.56 | $5.48 |
| Indicator | RYAM | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 41.16 | 56.30 |
| Support Level | $5.59 | $4.47 |
| Resistance Level | $5.92 | $5.45 |
| Average True Range (ATR) | 0.22 | 0.29 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 27.93 | 60.39 |
Rayonier Advanced Materials Inc is engaged in the production of cellulose specialties, a natural polymer used in the manufacturing of various specialty chemical products, including liquid crystal displays, filters, textiles and performance additives for pharmaceutical, food and other industrial applications. The company's products are used in a variety of applications, including cigarette filters, liquid crystal displays, paints, pharmaceuticals, and food. The company operates in the reportable segments of High Purity Cellulose, Paperboard, and High-Yield Pulp. The key revenue is derived from the High Purity Cellulose segment. Geographically, it derives a majority of its revenue from the United States.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.